This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!
A $25 billion buyout, a long-awaited FDA approval, two positive clinical studies, and one biopharma losing 37% of its value, are this week's top biotech stories.
3 Horrendous Health-Care Stocks This Week
Which health-care stocks experienced the agony of defeat this week?
Why Onconova Therapeutics Inc. Shares Imploded
Onconova Therapeutics reported disappointing phase 3 results for high-risk myelodysplastic syndrome drug rigosertib. Is this sell-off a buying opportunity or a reason to leave and not turn back?
Why Jabil Circuit, Inc., Onconova Therapeutics Inc., and Gogo Inc. Plunged Today
The long-awaited move from the Federal Reserve to cut back on its quantitative easing sent the markets roaring higher, but among the few decliners today, Jabil Circuit dropped almost 21%, Onconova Therapeutics fell 19%, and Gogo declined 16%. Find out why these stocks didn't join in the Fed-induced celebration Wednesday.
Why Onconova Therapeutics Inc. Shares Crashed
Onconova discontinues a late-stage trial for its lead experimental drug. Is this a classic overreaction by emotional traders or a reason to avoid Onconova?
Keep an Eye on Onconova, Enzymotec, DepoMed, and Omeros Today
Onconova, Enzymotec, DepoMed, and Omeros could make health care headlines this morning. Here’s why.